Ionis Pharmaceuticals' experimental drug, donidalorsen, administered through subcutaneous injection, showed a significant reduction in the rate of painful attacks for patients with hereditary angioedema. The patients received an 80 milligram dose of the drug every four or eight weeks.
Ionis Pharma's genetic disease drug succeeds in late-stage study
Reviewed by karthi
on
January 22, 2024
Rating:
No comments: